First Department of Pathological Anatomy, Medical Faculty of Masaryk University and St. Anne's University Hospital, 65691 Brno, Czech Republic.
Oncol Rep. 2012 May;27(5):1592-8. doi: 10.3892/or.2012.1687. Epub 2012 Feb 14.
Nestin has been detected in various malignancies and its expression correlates with advanced grade in some neoplasms. The aim of this study was to examine nestin expression in high-grade osteosarcomas and to determine its prognostic value. Using immunohistochemistry and immunofluorescence, we evaluated nestin expression in tumor tissue samples from 45 patients with high-grade osteosarcomas. In both methods, the frequency of nestin-positive tumor cells was classified into three categories (1+, 2+ and 3+ for immunohistochemistry; 1F+, 2F+ and 3F+ for immunofluorescence) and clinicopathological correlations were statistically evaluated and analyzed. Nestin-positive tumor cells were detected in all of the examined osteosarcomas using both immunohistochemistry and immunofluorescence, although the proportion of undoubtedly positive neoplastic cells varied in individual samples from a few nestin-positive tumor cells to diffuse nestin positivity. High levels of nestin expression detected by immunofluorescence (2F+ and 3F+) were associated with worse clinical outcomes (OS, p=0.031; EFS, p<0.001). However, high levels of nestin expression as measured by immunohistochemistry trended towards shorter patient survival rates but did not reach statistical significance. Despite significantly shorter survival rates observed in patients with high levels of nestin expression assessed by immunofluorescence, nestin does not seem to represent a powerful prognostic marker that would be superior to conventional methods.
巢蛋白已在各种恶性肿瘤中被检测到，其表达与一些肿瘤的高级别相关。本研究旨在检测高级别骨肉瘤中巢蛋白的表达，并确定其预后价值。我们使用免疫组织化学和免疫荧光法评估了 45 例高级别骨肉瘤肿瘤组织样本中巢蛋白的表达。在这两种方法中，巢蛋白阳性肿瘤细胞的频率被分为三个类别（免疫组化的 1+、2+和 3+；免疫荧光的 1F+、2F+和 3F+），并对临床病理相关性进行了统计学评估和分析。使用免疫组织化学和免疫荧光法均检测到所有检查的骨肉瘤中存在巢蛋白阳性肿瘤细胞，尽管个别样本中无疑阳性的肿瘤细胞比例从少数巢蛋白阳性肿瘤细胞到弥漫性巢蛋白阳性而有所不同。免疫荧光法检测到的巢蛋白高表达（2F+和 3F+）与较差的临床结局相关（OS，p=0.031；EFS，p<0.001）。然而，免疫组织化学检测到的巢蛋白高表达与患者生存率较短呈趋势相关，但未达到统计学意义。尽管免疫荧光法评估的巢蛋白高表达患者的生存率明显缩短，但巢蛋白似乎并不代表一种优于传统方法的强大预后标志物。
